JP6670297B2 - 抗セラミド抗体 - Google Patents

抗セラミド抗体 Download PDF

Info

Publication number
JP6670297B2
JP6670297B2 JP2017506827A JP2017506827A JP6670297B2 JP 6670297 B2 JP6670297 B2 JP 6670297B2 JP 2017506827 A JP2017506827 A JP 2017506827A JP 2017506827 A JP2017506827 A JP 2017506827A JP 6670297 B2 JP6670297 B2 JP 6670297B2
Authority
JP
Japan
Prior art keywords
sequence
antibody
antigen
binding fragment
ceramide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017506827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527544A (ja
JP2017527544A5 (https=
Inventor
ジミー ロトロ
ジミー ロトロ
リチャード コレスニック
リチャード コレスニック
Original Assignee
メモリアル スローン ケタリング キャンサー センター
メモリアル スローン ケタリング キャンサー センター
セラミド セラピュウティクス
セラミド セラピュウティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, メモリアル スローン ケタリング キャンサー センター, セラミド セラピュウティクス, セラミド セラピュウティクス filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2017527544A publication Critical patent/JP2017527544A/ja
Publication of JP2017527544A5 publication Critical patent/JP2017527544A5/ja
Application granted granted Critical
Publication of JP6670297B2 publication Critical patent/JP6670297B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017506827A 2014-08-07 2015-08-07 抗セラミド抗体 Active JP6670297B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462034453P 2014-08-07 2014-08-07
US62/034,453 2014-08-07
PCT/US2015/044144 WO2016022883A1 (en) 2014-08-07 2015-08-07 Anti-ceramide antibodies

Publications (3)

Publication Number Publication Date
JP2017527544A JP2017527544A (ja) 2017-09-21
JP2017527544A5 JP2017527544A5 (https=) 2018-09-13
JP6670297B2 true JP6670297B2 (ja) 2020-03-18

Family

ID=55264608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017506827A Active JP6670297B2 (ja) 2014-08-07 2015-08-07 抗セラミド抗体

Country Status (12)

Country Link
US (4) US10450385B2 (https=)
EP (2) EP4681733A3 (https=)
JP (1) JP6670297B2 (https=)
KR (1) KR102296416B1 (https=)
CN (1) CN107074949B (https=)
AU (1) AU2015300902B2 (https=)
CA (1) CA2957415C (https=)
IL (1) IL250374B (https=)
MX (1) MX391141B (https=)
RU (1) RU2717651C2 (https=)
SG (1) SG11201700787XA (https=)
WO (1) WO2016022883A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10537633B2 (en) 2016-03-04 2020-01-21 Jn Biosciences Llc Antibodies to TIGIT
CA3048224A1 (en) 2016-12-23 2018-06-28 Bluefin Biomedicine, Inc. Anti-sez6l2 antibodies and antibody drug conjugates
WO2020231629A1 (en) 2019-05-16 2020-11-19 Snake River Bioscience, Inc. Compositions and methods for the treatment of major depressive disorder
JP7623706B2 (ja) * 2019-06-06 2025-01-29 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド Ｃｄ７３に特異的な結合分子と結合分子の使用
US10975169B1 (en) 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
KR102245082B1 (ko) * 2020-02-14 2021-04-26 단국대학교 천안캠퍼스 산학협력단 치주인대전구세포 표면에 특이적으로 결합하는 두 가지 IgG 타입 단일클론항체 LG43, LG73 및 그의 용도
CN115811987A (zh) * 2020-03-18 2023-03-17 纪念斯隆凯特琳癌症中心 抗神经酰胺抗体
MX2022015157A (es) 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
EP4308231A4 (en) * 2021-03-16 2025-01-29 Memorial Sloan Kettering Cancer Center IMPROVING WOUND HEALING WITH ANTI-CERAMIDE ANTIBODIES
WO2024226646A2 (en) * 2023-04-25 2024-10-31 Memorial Sloan-Kettering Cancer Center Dlk1 -targeting antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPH02128697A (ja) * 1988-11-09 1990-05-17 Hoechst Japan Ltd 抗フコシルセラミドモノクローナル抗体
US7897753B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
RU2310393C1 (ru) 2006-02-16 2007-11-20 ФГУ Научно-исследовательский институт по изучению лепры Федерального агентства по здравоохранению и социальному развитию Российской Федерации Способ прогнозирования обострений лепрозных невропатий у больных лепрой
JP5924863B2 (ja) * 2007-05-06 2016-05-25 スローン ケタリング インスティテュート フォア キャンサー リサーチ Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
WO2009154026A1 (ja) * 2008-06-20 2009-12-23 国立大学法人岡山大学 石灰化小球に対する抗体及びその用途
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
CN102459335B (zh) * 2009-04-17 2015-11-25 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
FR2971250A1 (fr) * 2011-02-07 2012-08-10 Univ Nantes Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese
KR101256351B1 (ko) 2011-11-22 2013-04-19 김석진 필터 삽입공을 갖는 카메라 후드
WO2013125654A1 (ja) * 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
AU2013266069B2 (en) * 2012-05-25 2018-03-15 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
CN115811987A (zh) * 2020-03-18 2023-03-17 纪念斯隆凯特琳癌症中心 抗神经酰胺抗体

Also Published As

Publication number Publication date
US20230416409A1 (en) 2023-12-28
EP3177650A4 (en) 2018-01-03
JP2017527544A (ja) 2017-09-21
US20250197524A1 (en) 2025-06-19
IL250374B (en) 2021-04-29
AU2015300902A1 (en) 2017-03-02
RU2717651C2 (ru) 2020-03-24
MX391141B (es) 2025-03-21
US20190389970A1 (en) 2019-12-26
CA2957415C (en) 2021-07-13
RU2017105596A (ru) 2018-09-07
CN107074949A (zh) 2017-08-18
EP3177650A1 (en) 2017-06-14
US20170335014A1 (en) 2017-11-23
MX2017001686A (es) 2017-09-01
CA2957415A1 (en) 2016-02-11
NZ728981A (en) 2024-03-22
AU2015300902B2 (en) 2020-05-28
EP4681733A3 (en) 2026-05-06
US10450385B2 (en) 2019-10-22
KR102296416B1 (ko) 2021-09-01
IL250374A0 (en) 2017-03-30
SG11201700787XA (en) 2017-02-27
RU2017105596A3 (https=) 2019-04-17
BR112017002433A2 (pt) 2017-11-28
EP4681733A2 (en) 2026-01-21
KR20170066327A (ko) 2017-06-14
CN107074949B (zh) 2021-06-15
EP3177650B1 (en) 2025-11-05
WO2016022883A1 (en) 2016-02-11
US11447572B2 (en) 2022-09-20

Similar Documents

Publication Publication Date Title
US20250197524A1 (en) Anti-ceramide antibodies
US20250145699A1 (en) Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor
US20240174729A1 (en) High affinity pd-1 agents and methods of use
US20250051451A1 (en) Anti-b7-h3 monoclonal antibody and use thereof in cell therapy
JP2023109927A (ja) ヒトのがんを治療するための特異的抗ｃｄ３８抗体
CN106795220A (zh) 通过αβTCR结合多肽的多重施用的用于增强免疫抑制疗法的方法
BR112020016220A2 (pt) Anticorpos monoclonais biespecíficos pd-1/cd3 isolados ou fragmentos de anticorpos dos mesmos, composição farmacêutica e agente farmacêutico que compreendem os mesmos e uso dos ditos anticorpos ou fragmentos para prevenir, suprimir a progressão ou a recorrência dos sintomas e/ou tratar doenças autoimunes
CN109475625A (zh) 用于治疗脊髓性肌肉萎缩症的组合物和方法
JP2019070004A (ja) ヒトのがんを治療するための特異的抗ｃｄ３８抗体
JP6872756B2 (ja) 抗Ｍｙｌ９抗体
US8470325B2 (en) Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody
KR20220039720A (ko) 이중 특이성 항체
CN121311504A (zh) 用针对cd3和cd20的双特异性抗体治疗淋巴瘤的方法
US20240317844A1 (en) Anti-survivin antibodies for treatment of autoimmune diseases
BR112017002433B1 (pt) Anticorpos anticeramida
HK40062983A (en) Antigen binding molecules that bind pdgf-b and pdgf-d and uses thereof

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190913

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200228

R150 Certificate of patent or registration of utility model

Ref document number: 6670297

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250